Boberg M, Ahr H J, Beckermann B, Bühner K, Siefert H M, Steinke W, Wünsche C, Hirayama M
Bayer AG, Pharma Product Development and Research, Wuppertal, Germany.
Arzneimittelforschung. 1997 Aug;47(8):928-38.
The absorption, concentrations in plasma, metabolism and excretion of ramatroban ((+)-(3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid, CAS 116649-85-5, BAY u 3405) have been studied following a single intravenous, oral, or intraduodenal administration of 14C-labeled or nonlabeled compound to rats and dogs (dose range: 1-10 mg.kg-1). After intraduodenal administration of [14C]ramatroban, enteral absorption of radioactivity was rapid and almost complete both in bile duct-cannulated male rats (83%) and female dogs (95%). The oral bioavailability of ramatroban was complete in the dog but amounted to about 50% in the rat due to presystemic elimination. A marked food effect on the rate but not on the extent of absorption was observed in rats. The elimination of the parent compound from plasma occurred rapidly with total clearance of 1.2 l.h-1.kg-1 in male rats and 0.7 l.h-1.kg-1 in dogs. After oral administration to male rats AUC increased dose-proportionally between 1 and 10 mg.kg-1, whereas in Cmax an over-proportional increase was observed. Excretion of total radioactivity was fast and occurred predominantly via the biliary/fecal route in both species. The residues were low, 144 h after dosing less than 0.2% of the radioactivity remained in the body of rats. A considerable sex difference was found in rats following oral administration of ramatroban. In females a 3-fold higher AUC and a 1.7-fold longer half-life of unchanged compound, as well as 3-fold higher renal excretion of total radioactivity was observed. A marked species difference exists in the metabolism of ramatroban. In dogs the drug was almost exclusively metabolized via conjugation with glucuronic acid, whereas in rats oxidative phase I metabolism and glucuronidation were equally important. As a consequence enterohepatic circulation was much more pronounced in dogs (77%) than in rats (17% of the initial dose).
已对大鼠和犬单次静脉注射、口服或十二指肠内给予14C标记或未标记的雷马曲班((+)-(3R)-3-(4-氟苯基磺酰胺基)-1,2,3,4-四氢-9-咔唑丙酸,CAS 116649-85-5,BAY u 3405)后的吸收、血浆浓度、代谢和排泄情况进行了研究(剂量范围:1-10 mg·kg-1)。十二指肠内给予[14C]雷马曲班后,胆管插管的雄性大鼠(83%)和雌性犬(95%)的放射性肠吸收迅速且几乎完全。雷马曲班在犬体内的口服生物利用度完全,但在大鼠体内由于首过消除仅约为50%。在大鼠中观察到食物对吸收速率有显著影响,但对吸收程度无影响。母体化合物从血浆中的消除迅速,雄性大鼠的总清除率为1.2 l·h-1·kg-1,犬为0.7 l·h-1·kg-1。雄性大鼠口服给药后,1至10 mg·kg-1之间AUC呈剂量比例增加,而Cmax增加超比例。两种物种中总放射性的排泄都很快,主要通过胆汁/粪便途径。残留量很低,给药144小时后大鼠体内残留的放射性不到0.2%。口服雷马曲班后,大鼠存在明显的性别差异。雌性大鼠中,未变化化合物的AUC高3倍,半衰期长1.7倍,总放射性的肾排泄也高3倍。雷马曲班的代谢存在明显的物种差异。在犬中,药物几乎完全通过与葡萄糖醛酸结合进行代谢,而在大鼠中,氧化I相代谢和葡萄糖醛酸化同样重要。因此,肝肠循环在犬中(77%)比在大鼠中(初始剂量的17%)更为明显。